PSMA-1007
Phase 3Small molecule
PSMA-1007 is one of 37 small molecule programs targeting Magnetic Resonance Imaging. It is currently in Phase 3.
2
Indications
4
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Triptorelin Embonate
IpsenPhase 3
Lhrha
Johnson & JohnsonPhase 3
Docetaxel /m²
AstraZenecaPhase 3
PSMA-1007
AABX advanced biochemical compounds GmbH
Phase 3
Luteinizing Hormone Releasing Hormone
UUS Department of Veterans Affairs
Phase 3
Lupron Depot
RRepros Therapeutics Inc.
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Prostate Cancer3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PSMA-1007. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details